These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 10996633)

  • 1. Development of dendritic-cell based prostate cancer vaccine.
    Tjoa BA; Murphy GP
    Immunol Lett; 2000 Sep; 74(1):87-93. PubMed ID: 10996633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in active specific immunotherapy of prostate cancer.
    Tjoa BA; Murphy GP
    Semin Surg Oncol; 2000; 18(1):80-7. PubMed ID: 10617899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Active immunotherapy of prostate cancer with a focus on dendritic cells].
    Thomas-Kaskel AK; Veelken H
    Actas Urol Esp; 2007 Jun; 31(6):668-79. PubMed ID: 17896564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic-cell vaccination for prostate cancer.
    Thomas-Kaskel AK; Veelken H
    Immunotherapy; 2009 Jan; 1(1):63-72. PubMed ID: 20635974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity.
    Slovin SF
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):477-96. PubMed ID: 11525292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DC therapy for prostate cancer.
    Swindle PW; Tepes S; Clements J
    Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
    Minev BR; Guo F; Gueorguieva I; Kaiser HE
    In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients.
    Karbach J; Neumann A; Atmaca A; Wahle C; Brand K; von Boehmer L; Knuth A; Bender A; Ritter G; Old LJ; Jäger E
    Clin Cancer Res; 2011 Feb; 17(4):861-70. PubMed ID: 21163871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
    Small EJ; Fratesi P; Reese DM; Strang G; Laus R; Peshwa MV; Valone FH
    J Clin Oncol; 2000 Dec; 18(23):3894-903. PubMed ID: 11099318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer vaccines: current status and future potential.
    Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
    BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
    Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of metastasis.
    Dallal RM; Lotze MT
    Surg Oncol Clin N Am; 2001 Apr; 10(2):433-47, xi. PubMed ID: 11382596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
    Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
    BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with dendritic cells for prostate cancer.
    Thomas-Kaskel AK; Waller CF; Schultze-Seemann W; Veelken H
    Int J Cancer; 2007 Aug; 121(3):467-73. PubMed ID: 17514654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
    Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
    Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.